Dr. Abramson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
719 Thompson Ln
Ste 30860
Nashville, TN 37204Phone+1 615-936-8422Fax+1 615-343-3212- Is this information wrong?
Education & Training
- University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2003 - 2006
- Brigham and Women's HospitalResidency, Internal Medicine, 2000 - 2003
- University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2000
Certifications & Licensure
- TN State Medical License 2010 - 2025
- TN State Medical License 2020 - 2025
- TN State Medical License 2008 - 2025
- AL State Medical License 2020 - 2020
- PA State Medical License 2003 - 2008
Clinical Trials
- Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer Start of enrollment: 2011 Feb 01
- A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases Start of enrollment: 2011 Sep 01
- S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
- Join now to see all
Publications & Presentations
PubMed
- NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer.Taylor, B., Sun, X., Gonzalez-Ericsson, P., Sanchez, V., Sanders, M., Wescott, E., Opalenik, S., Hanna, A., Chou, S., Van Kaer, L., Gomez, H., Isaacs, C., Ballinger, T...> ;Cancer Discovery. 2024 Feb 8
- HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial.Zheqi Li, Otto Metzger Filho, Giuseppe Viale, Patrizia dell'Orto, Leila Russo, Marie-Anne Goyette, Avni Kamat, Denise A Yardley, Vandana Gupta Abramson, Carlos L Artea...> ;The Journal of Clinical Investigation. 2024 Feb 1
- 1 citationsAtezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer: The TBCRC 043 Phase 2 Randomized Clinical...Lehmann, B., Abramson, V., Dees, E., Shah, P., Ballinger, T., Isaacs, C., Santa-Maria, C., An, H., Gonzalez-Ericsson, P., Sanders, M., Newsom, K., Abramson, R., Sheng,...> ;JAMA Oncology. 2024 Feb 1
- Join now to see all
Press Mentions
- Ridner Concludes Five-Year, Multi-Site Trial to Assess Lymphedema PreventionApril 28th, 2022
- CDC Reports Major Drop in Routine Cancer Screenings Due to Ongoing PandemicAugust 14th, 2021
- A Brighter Outlook for Metastatic Breast CancerNovember 1st, 2019
- Join now to see all
Grant Support
- Pet-Mri For Assessing Treatment Response In Breast Cancer Clinical TrialsNational Cancer Institute2010–2012
- AKT Inhibitor Mk-2206 For Breast Cancers With A PIK3CA Mutation AND/OR PTEN LossNational Cancer Institute2011
Professional Memberships
- Member
Hospital Affiliations
- Vanderbilt University Medical CenterNashville, Tennessee
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: